ReviewBreast (Edinburgh, Scotland)2013
Mutational analysis of breast cancer: guiding personalized treatments.
Review in Breast (Edinburgh, Scotland), 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 21 citations in OpenAlex.
- Delineating intra-tumoral heterogeneity and tumor evolution in breast cancer using precision-based approaches.Frontiers in genetics · 2023Review
- The Role of Innate Immunity in the Pathogenesis of Breast Cancer.Breast care (Basel, Switzerland) · 2021Review
- Exceptional Response to Trastuzumab in a Heavily Pretreated Patient With ERBB3-Mutated Metastatic Breast Cancer.JCO precision oncology · 2021Article
- Exploiting DNA repair defects in triple negative breast cancer to improve cell killing.Therapeutic advances in medical oncology · 2020Article
- Metastatic Breast Cancer With ESR1 Mutation: Clinical Management Considerations From the Molecular and Precision Medicine (MAP) Tumor Board at Massachusetts General Hospital.The oncologist · 2016Article
- Analysis of different HER-2 mutations in breast cancer progression and drug resistance.Journal of cellular and molecular medicine · 2015Review
- Predictive value of microtubule-associated protein Tau in patients with recurrent and metastatic breast cancer treated with taxane-containing palliative chemotherapy.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2015Article
- Patient-derived xenograft models of breast cancer and their predictive power.Breast cancer research : BCR · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
The application of high throughput techniques to profile DNA, RNA and protein in breast cancer samples from hundreds of patients has profoundly increased our knowledge of the disease. However there remain many knowledge gaps that will require a long process of extended clinical correlation studies, deeper integrated 'omic analysis and functional annotation to address. This article reviews conclusions from recent breast cancer 'omics profiling' papers and considers pathways forward for extracting medically valuable information from large dimension data sets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.